







Jack has haemophilia A.





His medicine is Hemlibra.

Hemlibra is used for treating severe (FVIII <1%) haemophilia A, moderate (FVIII ≥1% and ≤5%) haemophilia A with a severe bleeding phenotype, and people with haemophilia A who have developed inhibitors to factor VIII



Jack and his parents wash their hands



and they get everything ready.





Jack's dad wipes his skin clean





then he holds his skin and gives Jack his Hemlibra.

Injection sites include: the thighs, the stomach (except for 5cm around the belly button) and the back of the upper arm (only if the injection is administered by a caregiver)



Jack holds a cotton pad on his skin to stop any bleeding.





They put everything away safely

and record it in Haemtrack.



Now it's time to play!





Special thanks for her advice and support on the content of this book goes to:

Lara Oyesiku

Clinical Nurse Manager, Basingstoke and North Hampshire Hospital; Southern Haemophilia Network.

For more information visit: takingemicizumab.com

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. You should also report side effects to Roche Products Ltd by emailing the Roche Drug Safety Centre at welwyn.uk_dsc@roche.com or calling +44 (0) 1707 367554. By reporting side effects you can help provide more information on the safety of this medicine.





This item has been developed by Roche Products Limited and Chugai Pharma UK Ltd M-GB-00011690 | June 2023